1. ESC 2008 Highlights*
Investor Teleconference
September 3, 2008
Brian Daniels
Senior Vice President, Global Development & Medical Affairs
Jack Lawrence
Vice President, Development Lead, Apixaban
**European Society of Cardiology
August 30 – September 3, 2008 Not For Promotional Use 1

2. Comments will be about the Company’s future plans and
prospects that may be forward-looking statements under
the Private Securities Litigation Reform Act of 1995.
We caution that actual results may differ materially from
those indicated by these forward-looking statements as
a result of various important factors, including those
discussed in the Company’s most recent annual report on
Form 10-K, periodic reports on Form 10-Q and current
reports on Form 8-K. These documents are available from
the SEC, the Bristol-Myers Squibb web site or from
Bristol-Myers Squibb Investor Relations. While we may elect
to update forward-looking statements at some point in the
future, we specifically disclaim any obligation to do so,
even if our estimates change.
Not For Promotional Use 2

3. Conference Call Agenda
Review overall apixaban development
program
Review results from Phase III ADVANCE-1
study in DVT prevention
Review results from Phase II APPRAISE-1
study in ACS
Review future key events
Not For Promotional Use 3

4. Apixaban Overview
Selective oral direct Factor Xa inhibitor
No organ toxicity or LFT abnormalities in
chronic toxicology studies
Good oral bioavailability
No food effect observed
Multiple routes of elimination (~25% renal)
Half-life ~12 hrs
Comprehensive Phase III program in
multiple indications
Not For Promotional Use 4

5. Apixaban Ongoing Phase 3 Clinical Development:
Pursuing Multiple Indications Simultaneously
Indication Trial N
VTE prevention (knee replacement) ADVANCE-1 3,000
VTE prevention (knee replacement) ADVANCE-2 3,000
VTE prevention (hip replacement) ADVANCE-3 4,000
VTE prevention (medical) ADOPT 6,500
Stroke prevention in AF (vs. warfarin) ARISTOTLE 15,000
Stroke prevention in AF (vs. aspirin) AVERROES 5,600
VTE treatment (initial vs. LMWH/heparin) AMPLIFY 4,800
VTE treatment (extended vs. placebo) AMPLIFY-EXT 2,400
VTE – venous thromboembolism Not For Promotional Use 5

6. Results in Phase 3 VTE Prevention
(ADVANCE-1)
Not For Promotional Use 6

7. ADVANCE-1 Study Design
Screening Period Treatment Period Follow-up Period
60 ± 3 days
30 days pre-surgery after the last
Days 1 or 2 through 12 ± 2
Post-surgery dose of study
drug
Subjects undergoing Randomization
elective knee
• Enoxaparin: 30 mg q 12 h; SC
replacement surgery
• Apixaban:2.5 mg BID; PO
Randomization post
surgery with treatment
initiated 12-24 hours
post surgery
Surgery Bilateral Venogram
Not For Promotional Use 7

8. Summary from ADVANCE-1
Rate of total VTE in patients randomized to 2.5 mg BID apixaban was
numerically similar to that observed in patients randomized to 30 mg BID
enoxaparin (9.0% vs. 8.9%, p=0.64)
– Apixaban was not shown to be inferior to enoxaparin. The actual
enoxaparin VTE rate (8.9%) was lower than the expected VTE rate of
16%, resulting in an inability to demonstrate noninferiority in this trial
The major bleeding event rate for apixaban was lower than for enoxaparin
(0.7% vs. 1.4%, p=0.053)
– The composite rate of major bleeding plus clinically relevant non-major
bleeding for apixaban was significantly less than the rate for
enoxaparin (2.9% vs. 4.3%, p =0.034)
There were no unexpected findings in adverse events for apixaban
compared to enoxaparin
– The ADVANCE-1 study demonstrated a low rate of elevated liver
function tests in patients randomized to apixaban, less than rate on
enoxaparin
These findings do not necessitate any changes to protocols in all ongoing
apixaban clinical trials
Not For Promotional Use 8

9. Conclusions from ADVANCE-1
Apixaban performed as expected from Phase 2
and had less bleeding than enoxaparin
Enoxaparin performed better on efficacy than
expected
Noninferiority criterion not satisfied
US filing for VTE prevention will not be
submitted in 2H09, as previously indicated
Not For Promotional Use 9

10. Results in Phase 2 ACS
(APPRAISE-1)
Not For Promotional Use 10

11. Unmet need for secondary prevention of
cardiovascular events persists in patients with ACS
Patients with acute coronary syndromes continue to have
recurrent ischemic events despite contemporary evidence-based
care, including revascularization and potent antiplatelet therapy
Oral anticoagulation (warfarin in WARIS-2 study; ximelagatran in
ESTEEM study) has been demonstrated to be superior to aspirin
following ACS
– However, warfarin is rarely used because of its narrow
therapeutic window and requirements for INR monitoring
– Ximelagatran (Exanta) was not approved in US due to
hepatotoxicity
No placebo-controlled trial of oral anticoagulation has been
performed in patients with ACS who are taking dual antiplatelet
therapy
Apixaban offers an opportunity to reduce recurrent ischemic
events beyond dual antiplatelet therapy
Not For Promotional Use 11

12. APPRAISE-1 was designed as a Phase 2, dose-
ranging, placebo-controlled, 6-month safety trial
Recent (≤7 days) Acute Coronary Syndrome
plus at least one additional risk factor
Phase A
Phase A •Randomized, double-blind.
•Randomized, double-blind.
Phase A = 547
Phase A = 547 •Study drug for 6 months.
1:1:1 •Study drug for 6 months.
1:1:1 •Aspirin ≤165 mg/d.
•Aspirin ≤165 mg/d.
•Clopidogrel per MD
•Clopidogrel per MD
discretion (stratified
discretion (stratified
Apixaban
Apixaban
Apixaban
Apixaban
Placebo
Placebo randomization)
randomization)
10 mg QD
10 mg QD
2.5 mg BID
2.5 mg BID
n=184
n=184
n=184
n=184
n=179
n=179 20 mg daily dose arms of
apixaban discontinued
Interim analysis (DSMB review) due to excess bleeding in
patients also receiving
Phase B
Phase B
Phase B = 1168
Phase B = 1168 dual antiplatelet therapy
3:1:1:2:2
3:1:1:2:2
Placebo Apixaban Apixaban Apixaban
Placebo Apixaban Apixaban Apixaban
Apixaban
Apixaban
n=427 2.5 mg BID 10 mg BID 20 mg QD
n=427 2.5 mg BID 10 mg BID 20 mg QD
10 mg QD
10 mg QD
n=138 n=248 n=221
n=138 n=248 n=221
n=134
n=134
Total = 1715
Total = 1715
Safety outcome: ISTH major or clinically relevant non-major bleeding (ISTH)
Efficacy outcome: cardiovascular death, MI, severe recurrent ischemia or ischemic stroke
Not For Promotional Use 12

13. Baseline characteristics demonstrate significant
co-morbidities, including advanced age and renal
insufficiency Placebo Apixaban
2.5 mg BID 10 mg QD
N 611 317 318
Median (IQR) Age, yrs 60 (52,69) 62 (53,69) 61 (52,69)
Age ≥75 yrs, % 11.0 14.2 12.3
Female, % 25.7 23.7 27.0
Mean weight, kg 81.8 81.3 82.5
Diabetes mellitus, % 23.2 21.8 22.3
Recent prior MI, % 4.7 7.9 5.7
Cerebrovascular disease, % 4.9 4.1 5.0
Peripheral vascular disease, % 3.9 6.6 4.4
CHF or LVEF < 40%, % 9.7 18.0 15.7
Residual multivessel CAD, % 25.0 26.8 25.8
Mild or moderate renal insufficiency, % 32.1 33.4 28.6
Not For Promotional Use 13

14. Broad ACS population was enrolled and patients
received standard of care background therapies
Placebo Apixaban
2.5 mg BID 10 mg QD
N 599 315 315
Index Event
ST-elevation MI, % 61.2 62.1 67.0
PCI, % 64.8 62.2 64.8
Clopidogrel, % 75.6 73.0 76.5
Mean time to study drug, days 4.3 4.2 4.1
Concomitant Medications During Trial
Aspirin, % 100.0 100.0 99.7
Clopidogrel, % 78.1 77.1 77.5
Beta blockers, % 92.7 92.4 93.3
Ace-Inhibitors or ARBs, % 88.1 86.7 82.9
Calcium blockers, % 21.5 25.4 20.0
Nitrates, % 39.1 45.4 43.8
Statins, % 88.1 87.0 87.9
Not For Promotional Use 14

15. Apixaban demonstrated dose-dependent reduction
in ischemic events compared with placebo
RRR 27% vs. placebo
10% p = n.s.
Placebo, n=611
8.7% RRR 39% vs. placebo
Apixaban 2.5 mg BID, n=317
p = n.s.
7.6%
8%
Apixaban 10 mg QD, n=318
6.0%
6% 5.4%
5.2%
4% 3.5%
3.1%
1.8%
2%
1.3%
0%
CV Death, MI, Sev Rec CV Death, MI or Stroke CV Death
Isch or Stroke
Not For Promotional Use 15

16. Dose-dependent reduction in ischemic events on
apixaban occurred independent of clopidogrel use
16% 15.4%
Placebo
CV Death, MI, SRI or Stroke
Apixaban 2.5 mg BID 12.9%
12% Apixaban 10 mg QD
9.3%
8.7%
7.6%
8%
6.5%
6.0%
5.6%
4.9%
4%
0%
Overall Clopidogrel No Clopidogrel
N 611 317 318 462 232 243 149 85 75
Not For Promotional Use 16

17. Apixaban demonstrated dose-dependent increase
in bleeding compared with placebo
10%
Placebo, n=599
7.9%
8%
Apixaban 2.5 mg BID, n=315
Apixaban 10 mg QD, n=315
5.7%
6%
4%
3.0%
1.9%
2% 1.6%
1.3%
1.0% 1.0%
0.8%
0.8%
0.3%
0.0%
0%
ISTH Major/CRNM ISTH Major TIMI Major/Minor TIMI Major
Not For Promotional Use 17

18. Other important safety findings in APPRAISE-1
There was a low frequency of study drug discontinuation due to
bleeding on apixaban:
Apixaban Apixaban
Placebo 2.5 mg BID 10 mg QD
Discontinuation due to
1.2% 1.9% 2.9%
bleeding
There was no signal for hepatotoxicity on apixaban in this
6-month study:
Apixaban Apixaban
Placebo 2.5 mg BID 10 mg QD
ALT > 3xULN* 2.7% 0 1.0%
* No cases of Hy’s law (concomitant increase in transaminase and bilirubin)
Not For Promotional Use 18

19. Summary from APPRAISE-1
This is the first experience with a direct factor Xa
inhibitor for secondary prevention in patients with
an acute coronary syndrome treated with
contemporary antiplatelet therapy
Although not powered to demonstrate significance
on the composite efficacy endpoint there was a non-
significant relative risk reduction compared to
placebo of 27% percent for 2.5 mg BID and 39% for
10 mg QD doses, and an associated dose-
dependent increase in bleeding
Planning to meet with Health Authorities to finalize
Phase 3 design and dosing
Not For Promotional Use 19

20. Key Events / Milestones
2008
Expect to present full ADVANCE-1 results
at American Society of Hematology
meeting in December
2009
Additional Phase III VTE prevention
results for EU registration
Initiate Phase III program for ACS
Not For Promotional Use 20

21. ESC 2008 Highlights*
Investor Teleconference
September 3, 2008
Brian Daniels
Senior Vice President, Global Development & Medical Affairs
Jack Lawrence
Vice President, Development Lead, Apixaban
**European Society of Cardiology
August 30 – September 3, 2008 Not For Promotional Use 21